

AD-A282 609



July 94

Oct 1992 - Jun 1994

4. TITLE AND SUBTITLE

Development of an *E. coli* 0157:H7 Specific Probe

PE: 61101F
PROJ: ILIR
TA: AE
WU: 31

6. AUTHOR(S)

Ferne K. McClesky

7. PERFORMING ORGANIZATION NAME(S)

Armstrong Laboratory (AFMC)
Epidemiology Research Division
2601 West Rod, Suite 2
Brooks AFB, TX 78235-5241

AL/AO-TN-1994-0001

9. SPONSORING/MONITORING AGENCY NAME(S)

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION AVAILABILITY STATEMENT

Approved for public release; distribution is unlimited.

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

E. coli strain 0157:H7 is an organism causing severe bloody diarrhea in humans. It's often contracted by ingestion of contaminated food. Present methods used for this diagnosis are time consuming, expensive and not of great sensitivity. The attempt to develop the DNA probe was to circumvent problems of present methods and provide better health care. The 60 megadalton plasmid of *E. coli* strain 0157:H7 was isolated by a modification of the Magic Miniprep method [Promega Scientific, Madison WI]. The plasmid was hydrolyzed with the restriction endonuclease PstI, ligated into pUCi8; the recombinant molecule was used to transform competent DH5 *E. coli* cells. Approximately 35 clones were obtained from the 0157:H7 plasmid library. This report ends the work on ILIRAE31. Further testing will be conducted under North East Research Cancer Institute Grant JON 725011XX.

14. SUBJECT TERMS

17. SECURITY CLASSIFICATION OF REPORT

unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE

unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT

unclassified

20. LIMITATION OF ABSTRACT

UL

**Best
Available
Copy**

The Report Documentation Number is a unique identifier that this information is available in the Report Documentation Instructions for filling out this form. For more information on optical scanning requirements, see the Report Documentation Instructions for filling out this form.

Block 1. Agency Use Only. Do not fill in.

Block 2. Report Date. Enter the date of the report (including day, month, and year) (e.g., 1 Jan 88). Most reports are dated.

Block 3. Type of Report and Period Covered. State whether report is normal, special, or other (e.g., applicable, enter in full). Enter date range (e.g., 1 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. Enter the title and subtitle of the part of the report that gives the most meaningful and complete information. If the report is prepared in more than one volume, repeat the primary title, and do not repeat subtitle. If include subtitle for the specific volume. If classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. Enter the contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as Prepared in cooperation with...; Trans. of...; To be published in... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12. Distribution Statement.

DDP	Unlimited Distribution
DDF	Domestic Distribution (U.S. only)
	Foreign Distribution (U.S. only)
	Agency Use Only
NASA	NASA only
NTIS	NTIS only

Block 13. Abstract. Include a brief (Maximum 100 words) factual summary of the report. Significant information contained in the report.

Block 14. Subject Terms. List words or phrases used to describe the report.

Block 15. Page Count. Enter the total number of pages.

Block 16. Price Code. Enter the price code (if any) (NTIS only).

Blocks 17-19. Security Classification. Enter the security classification of the report in accordance with U.S. Security Regulations (e.g., UNCLASSIFIED, CONFIDENTIAL, SECRET). If the report contains classified information, state classification on the top and bottom of the page.

Block 20. Limitation of Abstract. The abstract must be completed to the maximum length of 100 words. Enter either full or partial (if same as report). An entry of "full" indicates that the abstract is to be entered. If blank, the abstract is assumed to be unlimited.

TECHNICAL NOTE

Development of an Escherichia (*E. coli*) 0157:H7-Specific Probe


E. coli strain 0157:H7 is an organism causing severe bloody diarrhea in humans. It's often contracted by ingestion of contaminated food. Present methods used for this diagnosis are time consuming, expensive and not of great sensitivity. The attempt to develop the DNA probe was to circumvent problems of present methods and provide better health care.

The 60 megadalton plasmid of *E. coli* strain 0157:H7 was isolated by a modification of the Magic Miniprep method [Promega Scientific, Madison WI]. The plasmid was hydrolyzed with the restriction endonuclease PstI, ligated into pUCi8; the recombinant molecule was used to transform competent DH5 *E. coli* cells. Approximately 35 clones were obtained from the 0157:H7 plasmid library.

The resulting recombinant DNA molecules were isolated from the clones; these were hydrolyzed with PstI to free the 0157:H7 inserts. The PstI-cut recombinant DNA molecules were then electrophoresed and Southern-blotted onto nitrocellulose paper. The blots were probed with digoxigenin-labeled DNA of various plasmids found in other strains of *E. coli* -such as strains 88, 189, 221 that are responsible for various enterpathogenic disorders in humans. Insert DNA bands which did not hybridize with these plasmids were assumed to be possible 0157:H7-specific probe candidates. Eight clones contained such inserts. The inserts ranged in size from 1500 to 350bp. Sequencing of each insert is now in progress so that a ploymerase chain reaction [PCR] system can be developed. Once sequencing is completed, clinical trial will begin.

This report ends the work on ILIRAE31. Further testing will be conducted under North East Research Cancer Institute Grant JON 725011XX. In clinical trials conducted by the Clinical Bacteriology section specimens will be submitted to the Molecular Biology Institute at the University of Scranton, Scranton, PA.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

308 94-23446


94 7 25 096